Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Flexium joint supplement

This article was originally published in The Tan Sheet

Executive Summary

National ad campaign including TV, radio spots will commence in January for Pharmaton's three-product Flexium line. Designed by Eaton Marketing Group (West Caldwell, N.J.), ads feature tagline "When you move more freely, life is more spontaneous." Flexium Joint Comfort with SAM-e is available in 200 mg, 400 mg strengths and claims to "naturally help ease pain and stiffness from everyday activities." Joint Comfort & Cartilage Renewal, which offers 500 mg glucosamine combined with 200 mg SAM-e, "helps to renew cartilage" in "as little as two weeks," labeling says. Flexium supplements began hitting food, drug and mass shelves nationwide in September and retail for $18.99-$38.99; they are "the only brand available at major retailers" to offer original, patented form of SAM-e, Pharmaton says...

You may also be interested in...

Amid Aborted Sandoz Deal, A Silver Lining For Aurobindo?

The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.

NanoBio Nasal Antiseptic Launch Accelerated As COVID-19 Spikes Demand For Personal Sanitizers

“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.

COVID-19 Vaccines: Ex-FDA Leaders Urge High Bar For Emergency Use Authorization

Eschewing the standard approval mechanisms for COVID-19 vaccines is likely only appropriate in very limited high-risk populations, unless clinical efficacy outcomes are available, former FDA leaders say.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts